BIIB vs. TEVA, AEP, PNW, VRTX, REGN, GILD, ALNY, BMRN, NBIX, and INCY
Should you be buying Biogen stock or one of its competitors? The main competitors of Biogen include Teva Pharmaceutical Industries (TEVA), American Electric Power (AEP), Pinnacle West Capital (PNW), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), and Incyte (INCY).
Teva Pharmaceutical Industries (NYSE:TEVA) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, community ranking, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.
Teva Pharmaceutical Industries has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Biogen has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.
Biogen received 465 more outperform votes than Teva Pharmaceutical Industries when rated by MarketBeat users. Likewise, 71.93% of users gave Biogen an outperform vote while only 67.61% of users gave Teva Pharmaceutical Industries an outperform vote.
54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.2% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Teva Pharmaceutical Industries presently has a consensus target price of $15.75, indicating a potential downside of 6.97%. Biogen has a consensus target price of $286.50, indicating a potential upside of 27.37%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Biogen is more favorable than Teva Pharmaceutical Industries.
Biogen has a net margin of 12.07% compared to Biogen's net margin of -2.88%. Biogen's return on equity of 37.33% beat Teva Pharmaceutical Industries' return on equity.
Biogen has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Biogen had 17 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 33 mentions for Biogen and 16 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.42 beat Biogen's score of 0.31 indicating that Biogen is being referred to more favorably in the news media.
Summary
Biogen beats Teva Pharmaceutical Industries on 13 of the 18 factors compared between the two stocks.
Get Biogen News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
